cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma

Overview of attention for article published in Frontiers in oncology, August 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 15,171 followers.

RT @FrontOncology: New research: Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatm…

RT @FrontOncology: New research: Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatm…

RT @FrontOncology: New research: Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatm…

RT @FrontOncology: New research: Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatm…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.